OncoCyte Corporation (OCX) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 3 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for OCX is $8.00, representing a +150.0% upside from the current price of $3.2. Price targets range from a low of $8.00 to a high of $8.00.
